Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Motif closes in on approvals, potentially looking for partnership opportunities

US food and drug administration approval isn't there yet, but Motif continues to chug forwards
Motif closes in on approvals, potentially looking for partnership opportunities
Motif Bio is evaluating commercialisation options

In the world of US drug approvals, a positive result in a Phase 3 drug trial is generally celebrated with flourish: it might feel like you are nearing the end of the track. The finish line is near. One might think you're in the clear.

But it's not quite that simple.

WATCH: Motif Bio evaluating commercialisation options as decision time approaches

As Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB) knows all too well, getting a drug to market is no small task. The company is focused on a best-in-class drug, iclaprim, that targets bacteria resistant to most other commonly used antibiotics.

“Were spending a lot of time thinking about how we come to market in the US…” said Lumsden.  “We’re having some very constructive conversations with some potential partners.”

A potential partnership could be beneficial for Motif, from an efficiency and capital standpoint.

Major milestones achieved, more to come

Motif faces more work in the coming months as it continues to push towards final approval.

It passed a major milestone last year when it concluded a second phase III clinical trial on iclaprim and initiated a rolling submission to the US Food and Drug Administration, while also preparing a marketing authorization application to the European Medicines Agency. The submission is expected to be completed in the second quarter of 2018.

Potential partnerships

One question looming on Lumsden’s mind is figuring out the best way to come to market in the US. Should Motif go at it alone, or alongside a partner?

Lumsden says there are many paths Motif could go down: from a co-promotion effort, a licensing deal, or even a full M&A transaction.

“It’s our preferred path to try to find a partner for the US market,” said Lumsden. “If we have to do it ourselves, we can, we will, we just don’t think it’s the optimal way to do it.”

Lumsden stresses that in these types of situations, it can be far more effective and efficient to partner up. Potentially, that could be with another company that also has a single asset, perhaps in this case, a gram-negative antibiotic, which could complement nicely with iclaprim, which is a gram-positive antibiotic. However, all options are still on the table.

“We’re anticipating a decision, hopefully an approval from the FDA, in the first quarter [2019],” said Lumsden.

Medical science liaisons to play important role

About about six months ahead of the potential approval, there will likely be a push to increase awareness of iclaprim in both the medical community and hospital formulary committees. Generally, this is done by a team of medical science liaisons (MSLs), who use the scientific literature as an educational tool. In the case of Motif, it may make sense to team up with another partner, when it comes to forming the MSL team. Most people expect a decision on this to be made by the third quarter.

Beneficial for those with impaired kidneys

Iclaprim is a gram-positive antibiotic targeted especially to those who may have impaired kidneys, and/or face other compromising factors, such as diabetes. It is estimated that up to 26% of the 3.6mln patients hospitalized annually with acute bacterial skin and skin structure infections have kidney disease.

READ: Home plate beckons for Motif Bio

Antibiotics are the most commonly prescribed class of drug, representing a global market of $40bln. New, innovative approaches are needed, due to ever-evolving drug-resistant strains of bacteria.  

The numbers:

Motif just released their financial results for the year, which showed the company spent US$29.5mln on research and development -- a reflection of the work it has completed in clinical trials ahead of the regulatory application for iclaprim. Upon approval, iclaprim will be eligible for 10 years of market exclusivity in the US, starting from the date of first approval.

From a cash perspective, the figure was substantially down year-over-year, reflecting the high cost of getting a drug to market, which was US$34.8mln, and more importantly, Motif was sitting on US$22.7mln of cash at the year-end with access to US$20mln of debt financing.

Global and US opportunity looks bright

The global market for antibiotic drugs targeting difficult-to-treat infections, such as iclaprim, is an estimated US$3.0bln and is dominated by vancomycin, a traditional first-line treatment.

From an approval perspective, the future looks bright, compared to a stagnant few decades. From 2003 to 2010, only one new antibiotic was approved by the US Food and Drug Administration (FDA), and 10 since 2010. However, this year the FDA could approve as many as half a dozen new drugs, all from small players, such as Motif.

READ: Motif Bio to present new Iclaprim safety and efficacy data at top European conference

This weekend, Motif will present data at the 28th European Congress of Clinical Microbiology and Infectious Diseases which shows iclaprim still works on a variety of antibiotic-resistant pathogens such as methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) Staphylococcus aureus.

View full MTFB profile View Profile

Motif Bio Plc Timeline

Related Articles

June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use